Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2010

View Archived Issues

Nanotherapeutics submits IND to FDA for radiation exposure candidate

French scientists identify NTNG1 gene polymorphisms linked to alcohol and cocaine codependence

New MCH1 receptor antagonists claimed by sanofi-aventis

AstraZeneca's new TRPV1 antagonists inhibit capsaicin-evoked pain and flare

Atopaxar may reduce major cardiac events in subjects with ACS and CAD

Sanofi-aventis updates progress of second quarter 2010

Amgen discloses new selective inhibitors of hepatocyte growth factor receptor

Studies evaluate tamsulosin and doxazosin for urolithiasis

Czech scientists discover new antimicrobial peptides

Abbott presents new GlyT-1 inhibitors

Celldex to regain worldwide rights to rindopepimut from Pfizer

Merck & Co. describes novel gamma-secretase inhibitors

New activators of AMPK subunit alpha-1 claimed by Betagenon

INT-007 is bioequivalent to branded tablet for erectile dysfunction

Gilead submits MAA for fixed-dose Truvada/TMC-278 combination for HIV infection

Eisai launches Glufast in China for type 2 diabetes

Gynecologic Oncology Group to begin phase II trial of paclitaxel/ReoT3D combination

Johnson & Johnson submits MAA to EMA for TMC-278 for HIV infection

University of Rochester Medical Center begins study of muscular dystrophy therapeutics

Cladribine tablets are approved in Australia for MS

MSD and Faes Farma to market sitagliptin and sitagliptin/metformin in Spain

Levitra orodispersible tablet is approved in Europe for erectile dysfunction

EHDN supports statistical conclusions on MermaiHD trial's primary endpoint

ImmunoCellular Therapeutics presents update on ICT-107 and ICT-69

GSK investigates reports of narcolepsy following Pandemrix vaccination

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...